A photo of Rajaram Nagarajan.

Medical Director, Division of Oncology

Co-Clinical Director Cancer Survivorship Center

Professor, UC Department of Pediatrics

513-636-0670

513-636-3549

Board Certified

My Biography & Research

Biography

Dr. Nagarajan is a pediatric oncologist who specializes in the care of patients with cancer and patients who have completed their therapy.

Clinical Interests

Bone tumors; late effects of pediatric cancer therapy

Research Interests

Outcomes following cancer therapy and bone sarcomas

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Kidney Tumor, Sarcoma, Retinoblastoma, Cardio-Oncology

Research Divisions

Oncology, Cancer and Blood Diseases

My Locations

My Education

BA: Pre-Medical Sciences, Lehigh University, Bethlehem, PA, 1991.

MD: Medical College of Pennsylvania, Philadelphia, PA, 1995.

Internship and Residency: Pediatrics, Medical College of Virginia, Richmond, VA, 1998.

Fellowship Training: Hematology / Oncology / BMT, University of Minnesota, Minneapolis, MN, 2002.

MS: Clinical Research, University of Minnesota, Minneapolis, MN, 2002.

Certifications: Pediatrics, Pediatric Hematology / Oncology.

My Publications

Selected Publication

Cardiovascular Toxicities in Pediatric Cancer Survivors. Ryan, TD; Nagarajan, R; Godown, J. Cardiology Clinics. 2019; 37:533-544.

Long-term follow-up of surgical outcomes for patients with Wilms tumor and neuroblastoma. Cooke-Barber, J; Scorletti, F; Rymeski, B; Eshelman-Kent, D; Nagarajan, R; Burns, K; Jenkins, T; Dasgupta, R. Cancer. 2021.

The impact of proton therapy on cardiotoxicity following radiation treatment. Frankart, AJ; Nagarajan, R; Pater, L. Journal of Thrombosis and Thrombolysis. 2021; 51:877-883.

Solitary myofibroma preceding the development of multicentric myofibromatosis: A report of two cases with surveillance recommendations. Todd, K; Kim, HK; Szabo, S; Johnson, S; Pressey, J; Nagarajan, R; Sorger, J; Dasgupta, R; Turpin, B. Pediatric Blood and Cancer. 2020; 67.

Can a children's hospital still cut it? Comparing outcomes of pediatric, adolescent and young adult patients undergoing thoracic surgery for lung metastases. Scorletti, F; Cooke-Barber, J; Pressey, JG; Nagarajan, R; Turpin, B; Jenkins, T; Dasgupta, R. Pediatric Blood and Cancer. 2020; 67.

Outcomes after bloodstream infection in hospitalized pediatric hematology/oncology and stem cell transplant patients. Dandoy, CE; Kelley, T; Gaur, AH; Nagarajan, R; Demmel, K; Alonso, PB; Guinipero, T; Savelli, S; Hakim, H; Owings, A; et al. Pediatric Blood and Cancer. 2019; 66.

Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy. Calaminus, G; Jenney, M; Hjorth, L; Baust, K; Bernstein, M; Bielack, S; De Vos, P; Hogendoorn, PC W; Jovic, G; Krailo, M; et al. JMIR Research Protocols. 2019; 8.

Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group. Nagarajan, R; Gerbing, R; Alonzo, T; Johnston, DL; Aplenc, R; Kolb, EA; Meshinchi, S; Barakat, LP; Sung, L. Cancer Medicine. 2019; 8:4454-4464.

Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients. Ryan, TD; Nagarajan, R; Godown, J. Current Treatment Options in Oncology. 2019; 20.

Study of Delayed Antibiotic in Pediatric Febrile Immunocompromised Patients and Adverse Events. Fananapazir, N; Dandoy, C; Byczkowski, T; Lane, A; Nagarajan, R; Hariharan, S. Hospital pediatrics. 2019; 9:379-386.